Rohit Bishnoi, MD
Hematology · Riverview, FLNPI 1306035498
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,013 of the $2,349 with a category attached, or 85.7%. It is spread thinly across 32 manufacturers, the largest accounting for just 10.6% — the pattern of someone who eats at a lot of different presentations.
Across 77 payments — averaging $30.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tempus AI, Inc$250
- Pfizer$250
- AstraZeneca$216
- Ipsen Biopharmaceuticals, Inc$197
- Seagen Inc.$186
- Pharmacosmos Therapeutics Inc.$130
- plus $1K from 26 others
What the payments were for
- Food & beverage$2,01386%
- Education$33614%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Tempus AI, Inc | 9 | $250 |
| Pfizer | 10 | $250 |
| AstraZeneca | 3 | $216 |
| Ipsen Biopharmaceuticals, Inc | 2 | $197 |
| Seagen Inc. | 3 | $186 |
| Pharmacosmos Therapeutics Inc. | 6 | $130 |
| Regeneron Healthcare Solutions, Inc. | 4 | $125 |
| Genentech USA, Inc. | 4 | $121 |
| Johnson & Johnson | 1 | $97 |
| Adaptive Biotechnologies Corporation | 3 | $77 |
| Karyopharm Therapeutics Inc. | 3 | $75 |
| Novartis | 2 | $57 |
| Daiichi Sankyo Inc. | 3 | $54 |
| Lilly USA, LLC | 2 | $54 |
| Merck | 2 | $47 |
| Bayer | 2 | $46 |
| Boehringer Ingelheim | 2 | $37 |
| Myriad Genetic Laboratories, Inc. | 1 | $36 |
| Exelixis Inc. | 2 | $33 |
| Sanofi | 1 | $33 |
| Deciphera Pharmaceuticals Inc. | 1 | $29 |
| Acrotech Biopharma Inc. | 1 | $22 |
| Acera Surgical, Inc. | 1 | $20 |
| Bristol Myers Squibb | 1 | $20 |
| Inari Medical, Inc. | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| GE HealthCare | 1 | $18 |
| Beigene USA, Inc. | 1 | $18 |
| Amgen | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Sumitomo Pharma America, Inc. | 1 | $14 |
| Astellas Pharma US Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- IMFINZI$117
- SOMATULINE DEPOT$102
- ONIVYDE$102
How this compares
$2,349 in reported general payments places this provider in the 55th percentile of 79 hematology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 21 | $370,271 |
| EliquisApixaban | 46 | $38,459 |
| Ondansetron OdtOndansetron | 44 | $1,856 |
| Anastrozole | 122 | $1,744 |
| Letrozole | 36 | $1,637 |
| LoperamideLoperamide Hcl | 42 | $632 |
| Gabapentin | 38 | $460 |
| Promethazine Hcl | 32 | $443 |
| Tamoxifen Citrate | 18 | $409 |
| Oxycodone Hcl | 29 | $403 |
| Prochlorperazine Maleate | 18 | $396 |
| Ondansetron Hcl | 22 | $387 |
| Hydroxyurea | 18 | $354 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 25 | $323 |
| Acyclovir | 33 | $320 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $20 | $370,27121 claims |
| PfizerEliquis | $250 | $38,45946 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 79 hematology providers in Florida.
Other hematology in Riverview
- Javier Pinilla-IbarzTampa$1.6M
- Rami KomrokjiTampa$855K
- Ahmed ZakariAltamonte Springs$383K
- Alex Mejia GarciaVero Beach$302K
- Doris HansenTampa$141K
- Juan VarelaOrlando$131K
- Firas El ChaerMiami$105K
- Philip PancariOrlando$70K
- Melissa AlsinaTampa$64K
- Terrence BradleyMiami$53K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.